Gesynta Pharma AB Appoints Eva Johnsson as new Chief Medical Officer (CMO) / VP Clinical Development beQuoted
Intrauterine devices (IUDs) are drug-device combination products that are placed inside the uterus above the endometrium. IUDs contain a therapeutic agent used for contraception and have been shown to have …
Synthetic sex hormones, estrogens and/or progestogens, have been widely administered without sufficient long-term studies for decades to millions of pregnant women around the world and although most were banned in …
Endometriosis is a complex and multifaceted gynecological disorder characterized by the abnormal growth and presence of endometrial-like tissue outside the confines of the uterine cavity. It can lead to a …
Endometriosis (EM) is a chronic gynecological disorder characterized by the growth of endometrial-like tissue outside the uterus, leading to pain and infertility. Recent studies suggest that antioxidants may play a …
Endometriosis (EMS) is a common chronic gynecological disorder affecting 5%-10% of reproductive-age women, often causing infertility, dyspareunia, pain, and limitations in physical and sexual activities. This condition is defined by …
Endometriosis is caused by the migration of endometrial cells to locations outside the uterine lining. Despite the increasing prevalence of endometriosis, there has been limited research on genetic effects, and …
Mesothelioma in the past has been strongly associated with a history of asbestos exposure. Studies have shown that, on average, a higher dose of asbestos exposure is required for the …
Inadequate angiogenesis of endometriotic implants stimulated by the inflammatory microenvironment in the uterine region leads to the development of gynecological diseases, which significantly reduce the fertility and vitality of young …
TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development BioSpace